Sarcomatoid adrenocortical carcinoma with aggressive disease course: a rare case report and literature review Authors: Xin-Xin Xu, Guang-Fu Zhou, Cheng-Zhou Du, Xiao-Xin Gao, Xiao-Wei Guo, Ya-Long Li, Meng-Yuan Lu, Tian-Xiao He, Peng Chen, Hong-Tao Li Published: 2026 ABSTRACT AbstractIntroductionSarcomatoid Adrenocortical Carcinoma (SAC) is an extremely rare, highly aggressive, and poorly differentiated subtype of Adrenocortical Carcinoma (ACC). To date, only 38 cases have been reported worldwide. No standardized clinical diagnosis and treatment protocols have been established, and the prognosis of affected patients is extremely poor. This study reports a case of SAC in a 60-year-old female patient presenting with an abdominal mass, aiming to analyze the clinical characteristics, diagnosis, and treatment features of this rare tumor.Case presentationA 60-year-old female was admitted to our hospital due to an upper abdominal mass. Imaging examinations revealed a cystic-solid space-occupying lesion in the left retroperitoneum, and the tumor was highly suspected to be of adrenal cortical origin preoperatively. Given the rapid disease progression and the patient’s strong demand for urgent surgery, preoperative endocrine function examinations including cortisol, aldosterone, sex hormones and catecholamines were not performed. Laparotomy with complete tumor resection was Sarcomatoid Adrenocortical Carcinomasubsequently performed, and the final pathological diagnosis was SAC. The tumor was composed of 60% carcinomatous components and 40% high-grade sarcomatous components, classified as Fuhrman nuclear grade IV, with extensive parenchymal necrosis and vascular tumor thrombi observed in the lesion. One month after surgery, the patient developed extensive peritoneal metastasis and ascites, and eventually died on the 42nd day postoperatively.ConclusionSAC has non-specific manifestations and high diagnostic difficulty, with histopathology plus immunohistochemistry as the diagnostic gold standard. Highly invasive and rapidly progressive, it is mainly treated with surgical resection by following ACC protocols, yet their pathological features differ significantly. Given the extremely limited number of reported cases, current evidence is insufficient to either support or refute the efficacy of mitotane for SAC, and more multicenter large-sample studies are urgently needed.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1007/s12672-026-05500-4.Keywords: Sarcomatoid adrenocortical carcinoma, Immunohistochemical, Mitotane, Adrenocortical carcinoma staging systems, case report Background Sarcomatoid Adrenocortical Carcinoma (SAC) are an extremely rare and aggressive subtype of adrenocortical carcinoma (ACC), is an extremely rare, highly aggressive, and poorly differentiated subtype of ACC. Its diagnosis requires meticulous histological and immunohistochemical examinations [1]. The first known case was described by Okazumi et al. in 1987 [2]. A distinctive feature of these tumors is that they exhibit both carcinomatous and sarcomatous differentiation [3]. Case presentation A 60-year-old female patient was admitted on June 18, 2025, with a chief complaint of “discovery of an upper abdominal mass for over one month”. One month prior, the patient without obvious cause, which progressively enlarged and was accompanied by distending pain and discomfort after eating. Upper abdominal ultrasound revealed an intra-abdominal space-occupying lesion, considered to be a retroperitoneal tumor, and the patient was admitted as an outpatient with “intra-abdominal tumor”. Post-admission contrast-enhanced abdominal CT revealed: 1. A left retroperitoneal cystic-solid mass with locally unclear boundaries with the pancreatic tail, mostly considered as (1) solid pseudopapillary tumor, (2) mesenchymal tumor; left kidney and renal vein were compressed, and the left ovarian vein was significantly thickened and tortuous. 2. Enhanced nodule in the right posterior lobe of the liver during the arterial phase, mostly considered as hemangioma (Fig. 1). Preoperative tumor marker levels were as follows: AFP 2.40 µg/L, CEA 1.49ng/mL, CA-125 8.9U/mL, CA-153 4.5U/mL, CA-199 5.3U/mL. Based on the relevant examination results, the tumor was most likely of adrenocortical origin. After evaluating the patient’s general condition and excluding surgical contraindications, exploratory laparotomy was performed on June 23, 2025. During the operation, the mass was found to be located in front of the left kidney; the entire mass was meticulously dissected and completely resected, with careful protection of adjacent organs and blood vessels. Gross pathological examination revealed an irregular grayish-white to grayish-red tissue specimen measuring 11.0 cm × 9.0 cm × 9.0 cm; the cut surface was grayish-red and soft in texture. (Supplementary Fig. 1). Immunohistochemical results of the mass yielded that CKp (±), EMA (±), Inhibin-A (Focal+), Melan-A (+), Calretinin (−), Vimentin (+), Desmin (partial sarcomatous component+), SMA (partial sarcomatous component+), CD56 (+), Ki67 (sarcomatous component index ≈ 40%). Pathological diagnosis demonstrated that morphological changes combined with immunohistochemical staining results were consistent with adrenal cortical carcinosarcoma. The carcinomatous component corresponded to the conventional subtype of adrenal cortical carcinoma, accounting for approximately 60% of the tumor; the sarcomatous component was identified as high-grade sarcoma, comprising roughly 40%. The tumor was assigned a Fuhrman nuclear grade IV. Extensive parenchymal necrosis and vascular tumor thrombi were observed in the lesion. (Table 1; Fig. 2). In accordance with the 2022 WHO classification of adrenal cortical tumors, the final diagnosis was SAC (ICD-10: C74.00; ICD-11: 2D11.0) [4], a rare aggressive subtype of adrenocortical carcinoma composed of mixed epithelial and sarcomatoid components. Retrospective analysis of published literature indicated that the average survival of affected patients was around seven months. The patient was followed up postoperatively. Abdominal distension developed one month after surgery and the patient subsequently sought medical care locally. Imaging examination confirmed massive ascites, and the patient passed away on postoperative day 42. Abdominal enhanced computed tomography (CT) and three-dimensional reconstruction images of the tumor. A, B Axial and coronal images of the patient’s abdominal enhanced computed tomography (CT); C, D Three-dimensional imaging diagrams of the tumor in different orientations Table 1Results of Immunohistochemistry (IHC) and Special StainingMarkerIHC resultsCKpEMAInhibin-AMelan-ACalretininβ-cateninVimentinWeakly positiveWeakly positiveFocal positivePositiveNegativeNuclear negativePositiveDesminCaldesmonCalponinSMACD56Partially positive in sarcomatous componentsSlightly positive in sarcomatous componentsNegativePositive in some sarcomatous componentsPositiveSynFocal positiveCgANegativeCD31NegativeCD34NegativeSMARCA4PositiveP16Partially positiveHMB45NegativeINSM1NegativeKi-67Approximately 40% in hot spot areas of sarcomatous componentsMDM2NegativeMyoD1NegativePAX-8NegativeS100NegativeSOX10NegativeWT-1Negative Results of Immunohistochemistry (IHC) and Special Staining CKp EMA Inhibin-A Melan-A Calretinin β-catenin Vimentin Weakly positive Weakly positive Focal positive Positive Negative Nuclear negative Positive Desmin Caldesmon Calponin SMA CD56 Partially positive in sarcomatous components Slightly positive in sarcomatous components Negative Positive in some sarcomatous components Positive H&E and immunohistochemical staining of patients’ tumor tissues. A Hematoxylin and eosin (H&E) staining images of the patients’ tumor tissues (100×) (Supplementary Fig. 2). B–L IHC staining results of the tumor tissue for CKp, EMA, Inhibin-A, Melan-A, Calretinin, Vimentin, Desmin, SMA, CD56, Syn and Ki-67 in sequence (100×) Discussion A comprehensive search of the PubMed database identified 38 case reports on SAC, including the case presented herein (Table 2). Analysis of these cases revealed a patient age range at diagnosis from 23 to 80 years and an exceedingly poor overall prognosis, with a 5-year survival rate below 15% [5]. Published literature indicated a range of postoperative survival periods from a mere 2 days [6] to 30 months [7], with an average of 7.2 months. We posit that this dismal prognosis may be intrinsically linked to delays in diagnosis. Fine-needle aspiration biopsy in the diagnostic workup of SAC carries a potential risk of tumor dissemination; consequently, histopathological examination of the resected tumor remains the diagnostic “gold standard” [8]. The immunohistochemical staining results of the tissue specimen from this case provided critical evidence for the diagnosis and pathological classification of the disease. The results demonstrated that the molecular markers associated with the carcinomatous component in the tumor tissue, including CKp, EMA, inhibin-A, and Melan-A, all exhibited positive expression, indicating the presence of an epithelial-derived carcinomatous component in the tumor. Meanwhile, the mesenchymal markers related to the sarcomatous component, namely vimentin, desmin, and SMA, also showed positive expression, which confirmed the existence of a mesenchymal-derived sarcomatous component in the tumor and was consistent with the typical pathological feature of carcinosarcoma characterized by the coexistence of dual components. In addition, the positive expression of neuroendocrine-related markers CD56 and Syn suggested that the tumor might have neuroendocrine differentiation characteristics, thus providing supporting evidence for the heterogeneity of the disease. Table 2Clinical characteristics and outcomes of report sarcomatoid adrenocortical carcinoma casesAuthorYearAgeSexLocationSize (cm)Chief ComplaintTreatmentOutcomeOkazumi et al. [2]198746MaleR14 cmAbdominal distention, back painAdrenalectomy and nephrectomyDeath at 6 months post-opCollina et al. [17]198968FemaleL11 cmAbdominal discomfortResectionRecurrence at 2 months, Death at 6 months post-opDecorato et al. [18]199042FemaleL19 cmAbdominal and flank painResectionDeath at 7 months post-opFischler et al. [19]199229FemaleL12.5 cmAmenorrhea, fatigue, weight loss, body musculature, clitoromegaly, hirsutismResection with adjuvant treatment with mitotaneDeath at 8 months post-opBarksdale et al. [20]199379FemaleR9 cmSevere hypertensionNot reportedNot reportedLee et al. [6]199761MaleR12 cmFlank and back painRadical nephrectomy, right liver lobectomyDeath at 2 days post-opSturm et al. [21]200831MaleL12 cmAbdominal painResection with cisplatin and etoposideDeath at 3 months post-opColi et al. [22]201075FemaleL15 cmAbdominal painAdrenalectomy and splenectomyDeath at 12 months post-opSasaki et al. [23]201045MaleL17 cmAbdominal Pain, Fever, Nausea and vomitingNephrectomy, splenectomy, partial colectomy, and pancreatectomyDeath at 3 months post-opFeng et al. [24]201072MaleL7.1 cmLumbar back painResectionNot reportedBertolini et al. [25]201123FemaleL14 cmFatigue, decreased appetite, fixed mass in rectumadrenalectomyDeath at 14 months post-opThway et al. [26]201245MaleL24 cmBloating, back painAdrenalectomy, splenectomy, Nephrectomy combined with high-dose palliative chemotherapyDeath at 11 months post-opYan et al. [7]201272MaleR13 cmFlank painadrenalectomyDeath at 2.5 years post-opKao et al. [27]201345MaleR15 cmAbdominal pain, weight lossPartial nephrectomy and hepatectomyDeath at 7 months post-opMark et al. [28]201458MaleR12 cmFlank painAdrenalectomy and nephrectomyNo evidence of metastatic adrenal disease at 17 monthsShaikh et al. [29]201462FemaleR6.5 cmRight Upper Quadrant painadrenalectomyDeath at 4 months post-op, having declined adjuvant therapyWei et al. [30]201563FemaleL8 cmFatigue, flank painadrenalectomyNo recurrence at 1 month post-opWanis et al. [31]201568FemaleUnspecified13 cmIncidental finding during follow-up of lung adenocarcinomaRadical nephrectomyDeath at 223 days post-opWanis et al. [31]201565MaleUnspecified12.8 cmIncidental finding during claudication work-upRadical nephrectomyAlive at 4 months; unknown total survivalZhu et al. [32]201659MaleR5 cmAsthenia and weight lossadrenalectomyAlive at 6 months post op, refused further treatment and follow upIshikawa et al. [33]201669FemaleBilateralR:5.5cL:7.0 cmGeneral malaise and hypotensionResection4 months post-opIyidir et al. [34]201653FemaleBilateralR:9.0 cmL:8.5 cmAbdominal and flank pain, weight lossBilateral adrenalectomy, splenectomy, cholecystectomy, partial hepatectomy and nephrectomyDeath 1 month post-op due to pancreatic fistula development and multiorgan failurePapathomas et al. [35]201652MaleR24 cmAbdominal pain, fatigue, malaise, weight lossResection and mitotaneDeath at 4.5 months from diagnosisPapathomas et al. [35],201655MaleL16 cmAbdominal painResectionDeath at 4 months from diagnosisPapathomas et al. [35]201670FemaleR15 cmAbdominal pain, diarrheaResection and mitotaneDeath at 8 months from diagnosisSaegeretal [36]201753FemaleR13 cmHypertensionAdrenalectomy and partial hepatectomyAlive > 6 months post-op; alive at time of article but survival duration not clearSung et al. [37]201751MaleR15 cmNonspecificResectionDeath at 1.7 monthsSabrine et al. [38]202027FemaleR12 cmFlank painAdrenalectomyAlive at 6 months follow up without local recurrenceRexwana et al. [39]202037FemaleR10 cmFacial swelling and flushing, weight gain, palpitations, RUQ abdominal pain, generalized weakness and lethargyAdrenalectomyAlive 5 months post-op, received 3 rd cycle of chemotherapyRachh et al. [3]202278FemaleBilateralR:4.6 cmL:6.0 cmSevere back painNot reportedDeath within few months of diagnosisZhang et al. [40]202253FemaleR7.2 cmRUQ abdominal painSurgical resection ofDeath at 6 months after diagnosisBranham et al. [5]202278FemaleR27 cmFatigue and shoulder painRadical nephric to my and adrenalectomy, partial hepatectomyDeath at 7 days post-opJia et al. [41]202268FemaleR5.5 cmRight adrenal space-Right adrenal space-occupying lesionResection of right retroperitoneal space-occupying massDeath at 4 months post-opChen et al. [42]202380MaleBilateralR:5.9 cmL:7.2 cmIntermittent abdominal discomfort and diarrheaAdrenalectomyNot reportedBentaleb et al. [43]202451MaleL24 cmAbdominal painNot reportedDeath at 1 week after diagnosisKanzawa et al. [44]202566MaleL11 cmExperienced worsening blood pressure control, night sweats, shortness of breath during exertion, and palpitationsAdrenalectomyTwo years postoperatively, the patient has remained free from any signs of recurrence or metastasisXu et al. [45]202544MaleL6.8 cmPersistent, distending abdominal painTreatment with dabrafenib + trametinib and radiotherapy to the left adrenal glandDeath at 5 months after diagnosisPresent Case202560FemaleL11 cmAbdominal distentionAdrenalectomyDeath at 42 days post-opL = Left, R = Right, y = Year, cm = Centimeter Clinical characteristics and outcomes of report sarcomatoid adrenocortical carcinoma cases R:5.5c L:7.0 cm R:9.0 cm L:8.5 cm R:4.6 cm L:6.0 cm R:5.9 cm L:7.2 cm L = Left, R = Right, y = Year, cm = Centimeter Studies have indicated that only a small fraction (3%) of cases present with a maximum tumor diameter of ≤4 cm at diagnosis; therefore, clinicians should maintain a high index of suspicion for malignant lesions such as ACC in patients presenting with adrenal tumors exceeding 5 cm in diameter [9]. In adult primary SAC, the main somatic genetic alterations occur in genes that encode proteins involved in the WNT-β-catenin pathway, cell cycle and p53 apoptosis pathway, chromatin remodelling and telomere maintenance pathway, cAMP–protein kinase A pathway or DNA transcription and RNA translation pathways [10]. Given the extreme rarity of SAC, dedicated research remains limited, and standardized treatment protocols are lacking. Current therapeutic approaches often extrapolate from the diagnostic and therapeutic principles established for ACC, where surgical resection combined with postoperative adjuvant therapy represents the cornerstone of treatment [11]. Specifically, radical surgical resection offers the only potentially curative option for patients with stage I, II, and select stage III disease (Table 3) [12]. Based on the established diagnostic and staging criteria for ACC, the present case was assigned a pathological stage of pT4N0M0, corresponding to Stage IV disease. In the realm of postoperative adjuvant therapy, oral mitotane has historically been considered the first-line agent, although its clinical value remains a subject of ongoing debate [12]. Table 3Adrenocortical Carcinoma Staging Systems Proposed by the World Health Organization (WHO) and the European Network for the Study of Adrenal Tumors (ENSAT) [46]StagingWHOENSAT 2008IT1, N0, M0T1, N0, M0IIT2, N0, M0T2, N0, M0IIIT1-2, N1, M0, T3, N0, M0T1-2, N1, M0IVT1-4, N0-1, M1, T3, N1, M0 T4, N0-1, M0T1-4, N0-1, M1Staging definitions: M0 = No distant metastasis; M1 = Presence of distant metastasis; N0 = No positive lymph nodes; N1 = Presence of positive lymph nodes; T1 = Tumor with maximum diameter ≤ 5 cm; T2 = Tumor with maximum diameter > 5 cm; T3 = Tumor invasion into surrounding tissues; T4 = Tumor invasion into adjacent organs, or presence of venous tumor thrombus involving the vena cava or renal vein Adrenocortical Carcinoma Staging Systems Proposed by the World Health Organization (WHO) and the European Network for the Study of Adrenal Tumors (ENSAT) [46] Staging definitions: M0 = No distant metastasis; M1 = Presence of distant metastasis; N0 = No positive lymph nodes; N1 = Presence of positive lymph nodes; T1 = Tumor with maximum diameter ≤ 5 cm; T2 = Tumor with maximum diameter > 5 cm; T3 = Tumor invasion into surrounding tissues; T4 = Tumor invasion into adjacent organs, or presence of venous tumor thrombus involving the vena cava or renal vein Mitotane exerts its primary mechanism of action within the mitochondria, both by interfering with mitochondrial respiratory chain activity through the induction of cytochrome c oxidase deficiency in ACC cells and by inhibiting the function of Sterol-O-Acyl Transferase 1 (SOAT1). The latter leads to intracellular accumulation of free cholesterol and fatty acids, subsequently triggering endoplasmic reticulum stress and ultimately promoting ACC cell apoptosis [13, 14]. A meta-analysis encompassing 1249 ACC patients undergoing adjuvant mitotane therapy demonstrated that mitotane significantly reduced postoperative tumor recurrence and mortality in patients without distant metastasis [15]. However, a more recent randomized controlled trial (RCT) involving 91 patients with low-grade localized ACC compared adjuvant mitotane therapy (for at least 2 years) against observation alone. The study concluded that adjuvant mitotane therapy did not yield a statistically significant improvement in recurrence-free survival (RFS) for patients with low to moderate postoperative recurrence risk [16], thereby tempering clinical enthusiasm for this adjuvant treatment strategy. Conclusion After analyzing the included SAC cases, we found that due to the lack of a clear standardized treatment regimen for SAC, its current treatment mostly refers to the diagnostic and therapeutic strategies for ACC; however, there are significant differences between the two in pathological essence. Statistical results showed that four patients received mitotane, a chemotherapeutic drug commonly used in ACC treatment, after surgery; the other two patients who received chemotherapy were treated with an etoposide-platinum-based chemotherapy regimen. Among all patients who received chemotherapy, the one with the longest survival time was a patient treated with mitotane, with a recorded overall survival (OS) of 16 months after diagnosis. Additionally, thirty patients received only surgical treatment, with a postoperative survival time ranging from 1 day to 2.5 years. Due to the extremely low incidence of SAC and limited relevant case reports, the available data are insufficient to confirm that “surgery combined with adjuvant mitotane therapy” has a definite therapeutic effect in the treatment of SAC. Furthermore, most SAC patients have non-functional carcinosarcomas, and their symptoms at the time of consultation are caused by the tumor’s space-occupying effect, rather than specific manifestations of tumor biological progression. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 2. Acknowledgements Not applicable. Abbreviations Sarcomatoid adrenocortical carcinoma Adrenocortical carcinoma Computed tomography Immunohistochemistry Pan-cytokeratin Epithelial membrane antigen Smooth muscle actin Ki-67 antigen Recurrence-free survival Overall survival Sterol-O-Acyl Transferase 1 Randomized controlled trial European network for the study of adrenal tumors World Health Organization Author contributions XX and GZ: Responsible for investigation, visualization, writing the original draft, and reviewing & editing the manuscript. CD: Responsible for visualization and reviewing & editing the manuscript. XG and YL: Responsible for reviewing & editing the manuscript. XG and ML: Responsible for reviewing & editing the manuscript and visualization. TH: Responsible for supervision and reviewing & editing the manuscript. PC and HL: Responsible for supervision and reviewing & editing the manuscript. Funding The author(s) declared that financial support was received for the research, authorship, and/or publication of this article. This study was supported by the General Project of Gansu Provincial Joint Fund and the Science and Technology Program Project of Lanzhou City, Gansu Province, China. (grant nos. 2024-9-139) Data availability The original contributions presented in the study are included in the article material. Further inquiries can be directed at the corresponding author. Declarations Ethics approval This study has been ethically approved by the Ethics Committee of the 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army. This study was conducted in strict accordance with the guidelines for research involving human participants formulated by the Ethics Committee of the 940th Hospital of Joint Logistics Support Force of Chinese People’s Liberation Army。. Consent to participate Prior to participation, the participants were duly informed of their rights and responsibilities and provided explicit written informed consent. Consent for publciation The authors have obtained written consent to publish the images/details of the individual(s) included in this manuscript. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Xin-Xin Xu, Guang-Fu Zhou and Cheng-Zhou Du are co-first authors. Contributor Information Peng Chen, Email: chenp09@163.com. Hong-Tao Li, Email: lihongtao528@163.com. References Associated Data Supplementary Materials Supplementary Material 1. Supplementary Material 2. Data Availability Statement The original contributions presented in the study are included in the article material. Further inquiries can be directed at the corresponding author.